Marine organisms are sources of several natural compounds with potential clinical use. However, only a few marine-based pharmaceuticals have been approved for use due to limited knowledge on their biological activities. Here, we identified the functional role of fucoidan extracted from Fucus vesiculosus on ovarian cancer. Fucoidan increased the death of ES-2 and OV-90 cells, through a reduction in proliferation, cell cycle arrest, releases of cytochrome c, reactive oxygen species (ROS) generation, and endoplasmic reticulum (ER) stress. Additionally, fucoidan increased the concentration of cytosolic and mitochondrial calcium in both cells. The decrease of cell proliferation was controlled by the inactivation of PI3K and MAPK signaling cascades in ES-2 and OV-90 cells. In a toxicity assay with normal zebrafish larvae, fucoidan did not induce toxicity, cardiotoxicity, development, kinesis, and apoptosis at different concentrations. However, it disrupted tumor formation and vascular development in a zebrafish xenograft model and angiogenesis transgenic (Tg, fli1-eGFP) model, respectively. Collectively, the results indicate that fucoidan may be a novel pharmaceutical for the management of human ovarian cancer.
Introduction
Ovarian cancer is the leading cause of death among gynecological diseases [1] . It is responsible for about 22,240 new occurrences and 14,070 deaths and it is the 5th cause of cancer-related deaths in the USA in 2018 [2] . The high mortality rate is due to the absence of early symptoms, late diagnosis, limited therapeutic approaches, and the emergence of drug resistance [3] . When ovarian cancer is caught early, the 5-year survival rate of patients is close to 90%, but in most cases, the cancer is detected after metastasis, leading to low 5-year survival rate (less than 30%) [4] . Additionally, it has a high recurrence rate of about 70% and is resistant to already used anticancer drugs [5] . Of all ovarian cancers, epithelial ovarian cancer (EOC) in the ovarian surface epithelium is the most prevalent. More than 75% of EOC patients are diagnosed after the cancer has spread to various parts of the peritoneum and the body [6] . At this advanced stage, there is low treatment efficacy, disease recurrence, and 
Efficacy of Fucoidan on ROS Generation, Calcium Homeostasis, and Mitochondrial Membrane Potentials in Ovarian Cancer
To determine fucoidan-regulated cell properties of ovarian cancer, we analyzed reactive oxygen species (ROS) production using DCFH-DA analyzed by flow cytometry (Figure 2A ). Fucoidan (0, 25, 50, 100, 200 , and 300 μg/mL) gradually increased the production of ROS levels in both ES-2 and OV-90 cells up to 23.7% (p < 0.01) and 6.0% (p < 0.01). To identify alterations in cytosolic and mitochondrial calcium ion concentration, we stained the cells with Fluo-4 and Rhod-2 dyes ( Figure 2B ,C). In both ES-2 and OV-90 cells, 300 μg/mL fucoidan increased the cytosolic calcium ion levels by 7.3% (p < 0.01) and 3.6% (p < 0.001; Figure 2B) . Similarly, the level of mitochondrial calcium ion rose by 9.2% (p < 0.001) and 4.6% (p < 0.001) in ES-2 and OV-90 cells, under the same conditions as above ( Figure 2C ). Furthermore, we stained ES-2 and OV-90 cells with JC-1 dye after treating with fucoidan at the indicated concentrations to analyze if the change in the levels of mitochondrial calcium ion was due to the disruption of MMP by fucoidan ( Figure 2D ,E). Treatment with 300 μg/mL fucoidan induced the loss of MMP by 7.6% (p < 0.001) in ES-2 and 11.6% (p < 0.001) in OV-90 cells. In addition, fucoidan treatment induced fragmentation of nuclear DNA in ES-2 and OV-90 cells, evidenced by an increased terminal deoxynucleotidyl transferase dNTP nick end labeling (TUNEL) reaction ( Figure 2F ). Next, we 
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Fucoidan Regulates Intracellular Signals in Ovarian Cancer Cell Lines
To elucidate the fucoidan-induced intracellular signal transduction associated with proliferation and apoptosis, we conducted western blotting to investigate the phosphorylation of protein kinases including PI3K and MAPK pathways ( Figure 4 ). Phosphorylated cyclin D1, a key regulator of the cell cycle, was gradually inhibited by fucoidan (0, 100, 200, and 300 μg/mL) in ES-2 (up to 0.31-fold, p < 0.001) and OV-90 (up to 0.63-fold, p < 0.01) cells ( Figure 4A ). Additionally, fucoidan significantly inhibited the activation of PI3K pathway signaling cascades such as AKT, P70S6K, and S6 in ES-2 and OV-90 cells ( Figure 4B 
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Disruptiopn of Endoplasmic Reticulum (ER) by Fucoidan in Human Ovarian Cancer Cell Lines
To discover the efficacy of fucoidan on endoplasmic reticulum (ER) stress in ES-2 and OV-90 cell lines, we performed western blotting using proteins derived from both cell lines incubated with fucoidan (0, 100, 200, and 300 µg/mL). In fucoidan-treated ES-2 and OV-90 cell lines, the unfolded protein response (UPR)-signals (ER stress inducers)-inositol-requiring enzyme 1α (IRE1α), activating transcription factor 6α (ATF6α), and PKR-like ER resident kinase (PERK)-were activated in the ER transmembrane ( Figure 6A -C). Additionally, we confirmed that the cascades of the ER stress sensor-growth arrest-and DNA damage-inducible gene 153 (GADD153) and phosphorylated eukaryotic translation-initiation factor 2a (p-eIF2a) increased in fucoidan-treated ovarian cancer cells ( Figure 6D ,E). Moreover, the upstream of ER stress sensor-glucose-regulated protein 78 (GRP78) gradually increased in ovarian cancer cells by the increase in the concentration of fucoidan ( Figure 6F ). Next, after fucoidan treatment on ES-2 and OV-90 cells, we confirmed the expression of proteins related to the ER-mitochondria axis ( Figure 6G -L). Protein expression of voltage-dependent anion channel (VDAC), inositol 1,4,5-triphosphate receptor 1 (IP3R1), IP3R2, glucose-regulated protein 75 (GRP75), mitofusin 2 (MFN2), and vesicle-associated membrane protein-associated protein B/C (VAPB) all increased in ES-2 and OV-90 cells following fucoidan treatment. In addition, protein expression of microtubule-associated proteins 1A/1B light chain 3B (LC3B), beclin-1 (BECN1), and autophagy related 5 (ATG5), proteins involved in autophagy, also increased in response to fucoidan treatment ( Figure 6M -O).
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In Vivo Toxicity and Xenograft Analysis of Fucoidan Using Zebrafish
To validate the toxic effect of fucoidan, we performed toxicity assay of the response of normal zebrafish embryos to fucoidan ( Figure 7A ). Fucoidan did not induce toxicity, cardiotoxicity, and kinesis in the zebrafish embryos. Although their development was slightly decreased, there was no significant efficacy of fucoidan on the development of the embryos. To determine the effects of fucoidan on apoptosis in vivo, the zebrafish embryos were incubated with fucoidan and the apoptotic cells were tagged with acridine orange ( Figure 7B ). Our results showed that the apoptotic cells indicated by green fluorescence within the embryos were rarely detected in fucoidan-treated zebrafish. Although the expression of apoptosis-related genes including casp8 and casp9 decreased in 300 µg/mL fucoidan-treated zebrafish as indicated by quantitative RT-PCR analysis, there was no difference in the expression of casp3 and p53 genes in comparison with the control (Figure 7C -F). There was an efficient suppression of tumor volume and formation in fucoidan-treated transgenic model compared with the vehicle-treated model ( Figure 7G,H) .
(G-L) The activation of ER-mitochondria axis-associated proteins, (G) VDAC, (H) IP3R1, (I) IP3R2, (J) GRP75, (K) MFN2, and (L) VAPB was analyzed by western blotting in fucoidan treated ES-2 and OV-90 cells. (M-O) The activation of autophagy-associated proteins, (M) LC3B, (N) BECN1, and (O) ATG5 was observed through western blot in ES-2 and OV-90 cells incubated with fucoidan. The graph of the signals was calculated compared with total signal or α tubulin (TUBA). *** p < 0.001, ** p < 0.01, and * p < 0.05 show significances.
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Inhibitory Effects of Fucoidan on Angiogenesis In Vivo and In Vitro
To identify if fucoidan has anti-angiogenic effects, we used the zebrafish Tg(fli1:eGFP) line generated for the study of vascular system. Treatment with fucoidan (300 μg/mL) disrupted the vascular development of zebrafish embryo, especially dorsal longitudinal anastomotic vessel (DLAV), intersegmental vessel (ISV), and dorsal aorta (DA) parts compared with vehicle-treated fli1 Tg models ( Figure 8A ). In accordance with the results, the angiogenesis-related genes such as vascular endothelial growth factor Aa (vegfaa), vegfc, fms related tyrosine kinase 1 (flt1), flt4, kinase insert domain receptor (kdr), and kdr like (kdrl) were dramatically decreased in fucoidan-incubated fli1 Tg zebrafish 
To identify if fucoidan has anti-angiogenic effects, we used the zebrafish Tg(fli1:eGFP) line generated for the study of vascular system. Treatment with fucoidan (300 µg/mL) disrupted the vascular development of zebrafish embryo, especially dorsal longitudinal anastomotic vessel (DLAV), intersegmental vessel (ISV), and dorsal aorta (DA) parts compared with vehicle-treated fli1 Tg models ( Figure 8A ). In accordance with the results, the angiogenesis-related genes such as vascular endothelial growth factor Aa (vegfaa), vegfc, fms related tyrosine kinase 1 (flt1), flt4, kinase insert domain receptor (kdr), and kdr like (kdrl) were dramatically decreased in fucoidan-incubated fli1 Tg zebrafish compared with the control (Figure 8B-G) . Next, we compared the anti-angiogenic effects of fucoidan with conventional anti-cancer drugs including cisplatin and paclitaxel in human ovarian cancer cell lines. The mRNA expression of VEGFs (VEGFA-VEGFD) was reduced by fucoidan in ES-2 and OV-90 cells ( Figure 8H-K) . Their expression was synergistically decreased by a combination of fucoidan with cisplatin or paclitaxel compared with individual treatment. Even though the synergy of fucoidan with cisplatin or paclitaxel on FLT1 expression was indicated only in ES-2 cells, mRNA expression of FLT4 and KDR was highly inhibited in ES-2 and OV-90 cells incubated with the combined treatment compared with those incubated with the individual treatments ( Figure 8L-N) .
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Discussion
Fucoidan caused a 40% growth inhibition in ES-2 and OV-90 cells at a dose of 300 μg/mL, and it induced the apoptosis in ovarian cancer cells after 48 h incubation. Additionally, fucoidan triggered the depolarization of MMP, production of ROS, and an increase in calcium ion concentration in cytosol and mitochondria. Fucoidan inhibited PI3K/MAPK intracellular signal pathways; however, it activated the apoptotic cascades and ER stress sensor proteins in the ovarian cancer cells as illustrated in Figure 9 . Although fucoidan did not affect the normal zebrafish in vivo, it highly decreased tumor formation and angiogenesis in the xenograft and fli1 Tg models, respectively. Additionally, fucoidan suppressed the expression of angiogenesis-related genes in vivo and in vitro by enhancing the efficiency of chemotherapeutic agents. These data indicate that fucoidan can be used as a novel drug for the management and treatment of ovarian cancer. 
Fucoidan caused a 40% growth inhibition in ES-2 and OV-90 cells at a dose of 300 µg/mL, and it induced the apoptosis in ovarian cancer cells after 48 h incubation. Additionally, fucoidan triggered the depolarization of MMP, production of ROS, and an increase in calcium ion concentration in cytosol and mitochondria. Fucoidan inhibited PI3K/MAPK intracellular signal pathways; however, it activated the apoptotic cascades and ER stress sensor proteins in the ovarian cancer cells as illustrated in Figure 9 . Although fucoidan did not affect the normal zebrafish in vivo, it highly decreased tumor formation and angiogenesis in the xenograft and fli1 Tg models, respectively. Additionally, fucoidan suppressed the expression of angiogenesis-related genes in vivo and in vitro by enhancing the efficiency of chemotherapeutic agents. These data indicate that fucoidan can be used as a novel drug for the management and treatment of ovarian cancer. In recent decades, reports on the establishment of anti-cancer agents for the reduction of cancerrelated death rates have increased tremendously. Since the side effects of synthetic agents and recurrence rate of ovarian cancer, the finding of anti-cancer agents from natural compounds is needed. Additionally, combination therapies of synthetic drugs and natural compounds have been studied for the improvement of chemosensitivity in ovarian cancer. Fucoidan, a macromolecule derived from brown algae, has been extensively studied due to their diverse biological functioning including anti-cancer, anti-oxidant, and anti-inflammatory effects. Fucoidan belongs to complex sulfated polysaccharides commonly existed in the cell walls of brown algae [14] . Although fucoidan has functional roles in the prevention of various cancers, its biological activities have not been reported in ovarian cancer.
In previous studies, fucoidan induced apoptotic mechanism in prostate cancer cells [26] and animal models [27] . Additionally, fucoidan stimulated cell death in bladder cancer [28] and colon cancer [18] . In agreement with these results, fucoidan inhibited cell growth and induced cell death in both ovarian cancer cells in our study. PCNA, a well-known marker for cell proliferation [29] , was decreased by fucoidan in ES-2 and OV-90 cells. Similar to cell cycle progression regulated by fucoidan in several cancer cells including bladder cancer, colon cancer, and leukemia [30] , fucoidan increased sub G1 phase and deceased G2/M phase in ES-2 and OV-90 cells. According to a previous study, fucoidan increased the generation of ROS in human ovarian cancer cell lines [31] . Previous reports suggested that fucoidan increased ROS generation, mitochondrial oxidative damage, MMP depolarization, production of cytochrome c, decrease of X-linked inhibitor of apoptosis protein (XIAP), and cleavage of caspase-3 and caspase-9, which are similar with our results [32] .
Mitochondria are crucial organelles associated with the intrinsic apoptotic pathways [33] . Mitochondrial cell death is accompanied with activation of caspases, secretion of cytochrome c, increased mitochondrial Ca 2+ , mitochondrial membrane permeabilization and stimulation of proapoptotic signals such as Bax and Bak, [34] . The excess of mitochondrial Ca 2+ can induce the secretion of pro-apoptotic signals through the destruction of the mitochondria. Additionally, malfunction of mitochondria in cancer cells promotes the alteration in the Ca 2+ levels of cytosol and cell death [35] . Moreover, the intracellular free Ca 2+ inhibits anti-apoptotic protein (Bcl-2) and activates pro-apoptotic proteins (Bad and Bcl-XL), leading to early or late apoptosis [36] . In our experiments, we used 2-APB, BAPTA/AM, and ruthenium red to understand the detailed calcium regulation of fucoidan. 2-APB inhibits calcium concentration through regulation of both IP3Rs and TRP channels [37, 38] . Since BAPTA/AM has four carboxylic acid functional groups, it combines with two calcium ions and acts In recent decades, reports on the establishment of anti-cancer agents for the reduction of cancer-related death rates have increased tremendously. Since the side effects of synthetic agents and recurrence rate of ovarian cancer, the finding of anti-cancer agents from natural compounds is needed. Additionally, combination therapies of synthetic drugs and natural compounds have been studied for the improvement of chemosensitivity in ovarian cancer. Fucoidan, a macromolecule derived from brown algae, has been extensively studied due to their diverse biological functioning including anti-cancer, anti-oxidant, and anti-inflammatory effects. Fucoidan belongs to complex sulfated polysaccharides commonly existed in the cell walls of brown algae [14] . Although fucoidan has functional roles in the prevention of various cancers, its biological activities have not been reported in ovarian cancer.
Mitochondria are crucial organelles associated with the intrinsic apoptotic pathways [33] . Mitochondrial cell death is accompanied with activation of caspases, secretion of cytochrome c, increased mitochondrial Ca 2+ , mitochondrial membrane permeabilization and stimulation of pro-apoptotic signals such as Bax and Bak, [34] . The excess of mitochondrial Ca 2+ can induce the secretion of pro-apoptotic signals through the destruction of the mitochondria. Additionally, malfunction of mitochondria in cancer cells promotes the alteration in the Ca 2+ levels of cytosol and cell death [35] . Moreover, the intracellular free Ca 2+ inhibits anti-apoptotic protein (Bcl-2) and activates pro-apoptotic proteins (Bad and Bcl-XL), leading to early or late apoptosis [36] . In our experiments, we used 2-APB, BAPTA/AM, and ruthenium red to understand the detailed calcium regulation of fucoidan. [37, 38] . Since BAPTA/AM has four carboxylic acid functional groups, it combines with two calcium ions and acts as a calcium chelator [39, 40] . Ruthenium red is a potent inhibitor of intracellular calcium release by regulation of ryanodine receptors [41] . Fucoidan increased calcium concentration of ovarian cancer cells through IP3Rs, TRP channels and ryanodine receptors via ER-mitochondria tethering. Therefore, our study demonstrated that fucoidan induced the cell death of human ovarian cancer cells by increasing the concentration of calcium in both cytoplasm and mitochondria. Additionally, fucoidan stimulated the loss of MMP in ovarian cancer cell lines through the excess ROS levels.
2-APB inhibits calcium concentration through regulation of both IP3Rs and TRP channels
Ca 2+ and ROS can affect each other for maintaining cell physiology. ROS can regulate Ca 2+ signals, and Ca 2+ plays a vital role in ROS production. The increased Ca 2+ concentration induces the activation of ROS producing enzymes and generation of free radicals [42] . High concentration of Ca 2+ increases the ROS production through stimulation of respiratory chain activity. Moreover, the increased ROS induces Ca 2+ releasing, ER stress, and further ROS production through ER-calcium channels. Therefore, the elevated ROS production and Ca 2+ concentration can lead to mitochondrial swelling and cell death through induction of mitochondrial membrane permeability transition and releasing of pro-apoptotic factors [43] .
The intracellular signals are crucial for the regulation of cell survival and proliferation. Fucoidan increased cell death in several cancers by inhibiting the activation of cyclin D1, cyclin E, cyclin-dependent-kinases (Cdks), PI3K, and MAPK [44] [45] [46] . Therefore, the inhibition of PI3K/AKT signals in cancer cells might be a useful method to the management of cancer [47] . Herein, we identified that fucoidan reduced the activities of cyclin D1, PI3K/MAPK signals. In other studies, fucoidan decreased the expression of anti-apoptotic signals including Bcl-2, Bcl-XL, and MCL-1 in breast cancer [48, 49] . Furthermore, fucoidan promotes cell death in human hepatocellular carcinoma (HCC) cells through cleavage of caspases [50] . Moreover, fucoidan induces the death of HCC cells through activation of caspases-7, -8, and -9 [44] . Fucoidan upregulates toll-like receptor 4 (TLR4)/CHOP-mediated caspase-3 and poly (ADP-ribose) polymerase (PARP) stimulation to promote anti-cancer effects of cisplatin in human lung cancer cells [51] . Our results indicate that fucoidan increased cell death via the cleavage of caspase-3 and caspase-9 and the release of cytochrome c in ES-2 and OV-90 cells. Additionally, fucoidan showed synergistic effects with cisplatin or paclitaxel, causing ovarian cancer cell death. Moreover, ER play pivotal role in diverse intracellular mechanism including protein translocation, protein folding, and post-transcriptional modification [52] . Previous studies reported that fucoidan promotes cancer cell apoptosis through the induction of ER stress. Fucoidan induces cell death by regulating GRP78 and ER protein 29 in breast cancer and colorectal cancer [53] . Consistent with the result of these studies, fucoidan increased ER stress sensor signals such as IRE1α, ATF6α, PERK, GADD153, eIF2α, and GRP78 in ES-2 and OV-90 cells. Alternative pattern of signals associated with the ER-mitochondria axis regulated by fucoidan suggest that anti-cancer effect of fucoidan is accompanied with the interaction of ER and mitochondria. Angiogenesis is the development of new blood vessels and, here, fucoidan inhibited the angiogenesis of cancer cells. The angiogenesis network is crucial for provision of oxygen and nutrition in cancer cells [54] . Thus, the repression of angiogenesis is used in diverse anti-cancer therapies. Fucoidan decrease hypoxia-stimulated H 2 O 2 production, hypoxia-inducible factor-1 (HIF-1) formation, generation of VEGF, cell migration, and invasion of T24 cells. Additionally, low molecular weight fucoidan inhibits tube generation through hypoxic HUVECs and blood capillary production in the cancer cells [55] . Fucoidan suppresses cancer metastasis through reducing of VEGF and matrix metalloproteinases in Lewis tumor-xenograft mice [56] . Similarly, treatment with fucoidan repressed the mRNA expression of angiogenesis related genes including VEGFA, VEGFB, VEGFC, VEGFD, FLT-1, FLT-4, and KDR in the ovarian cancer cells. Moreover, in in vivo angiogenic Tg zebrafish model, fucoidan completely suppressed vasculature development, whereas it did not affect normal zebrafish embryos. Collectively, fucoidan inhibited PI3K, MAPK, the mitochondrial-mediated apoptotic signaling, and angiogenesis and activated ER stress to induce cell death of human ovarian cancer cells.
Material and Methods

Chemicals
Fucoidan (catalog number: F8315), cisplatin (catalog number: P4394), and paclitaxel (catalog number: T7408) were bought from Sigma-Aldrich (St. Louis, MO, USA). The antibodies used are indicated in Table 1 . U0126 (catalog number: EI282), SP600125 (catalog number: EI305), and SB203580 (catalog number: EI286) were bought from Enzo Life Sciences, Inc. (Farmingdale, NY, USA), and LY294002 (catalog number: 9901) was bought from Cell Signaling Technology, Inc. (Danvers, MA, USA). 
Cell Culture
ES-2 and OV-90 were bought from American Type Culture Collection (Manassas, VA, USA) and incubated in McCoy's 5A Medium (10% fetal bovine serum; FBS: heat inactivation before use; 56 • C, 30 min) at 37 • C in a CO 2 incubator. The ovarian cancer cell lines were incubated with diverse doses of fucoidan with or not with inhibitors of various cell signals.
Cell Proliferation Analysis
Cell growth was observed through the Cell Proliferation ELISA, BrdU Kit (Roche, Basel, Switzerland) according to the manufacturer's recommendations. ES-2 and OV-90 cell lines were incubated in a 96-well plate for 24 h in serum-free McCoy's 5A Medium. Next, the cells were incubated with fucoidan or fucoidan with each signaling inhibitor such as LY294002, U0126, SP600125, and SB203580. After 48 h treatment, 10 mM BrdU was co-treated for 2 h at 37 • C. Next, the cells were fixed and treated with anti-BrdU-peroxidase working solution for 90 min. Lastly, the absorbance values of the cells with 3,3 ,5,5 -tetramethylbenzidine were estimated at 370 nm and 492 nm using Epoch microplate spectrophotometer (BioTek, Winooski, VT, USA). The experiment was conducted triplicate.
Observation of Immunofluorescence
PCNA were observed using immunofluorescence microscopy. The cells were incubated with or without fucoidan (300 µg/mL) at 37 • C for 48 h in a CO 2 incubator and tagged with mouse anti-human monoclonal PCNA antibody (Santa Cruz Biotechnology, Dallas, TX, USA). Next, cells were treated with goat anti-mouse IgG Alexa 488 (Invitrogen, Carlsbad, CA, USA) at a dilution of 1:200 for 1 h at room temperature. Then, the cells were rinsed through 0.1% BSA -PBS and double staining with 4 ,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO, USA). The image was observed via an LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany).
Annexin V and PI Staining
The death of ovarian cancer cell lines promoted by fucoidan was estimated through an FITC Annexin V apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ, USA). The ovarian cancer cell lines (5 × 10 5 cells) were incubated on 6-well plates and treated with fucoidan (0, 25, 50, 100, 200, and 300 µg/mL) for 48 h at 37 • C. The cells were rinsed with PBS. The cell suspension (100 µL, 1 × 10 6 cells) was stained with Annexin V (5 µL) and propidium iodide (PI; 5 µL) for 15 min at room temperature in the dark. The fluorescent intensity was determined through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was repeated three times.
Cell Cycle Assay
The cell cycle progression of ES-2 and OV-90 cells was observed through PI. The cells on 6-well plates were treated with fucoidan (0, 25, 50, 100, 200, and 300 µg/mL) for 48 h at 37 • C and 5% CO 2 . The cells were rinsed with PBS. Next, cells were resuspended (1 × 10 6 cells) and treated with RNase A (5 µL) and PI (5 µL) for 30 min at room temperature in the dark. The fluorescent intensity was calculated through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was repeated three times.
Determination of Cellular ROS
Generation of ROS was observed by 2 ,7 -Dichlorofluorescin diacetate (DCFH-DA, Sigma). The cells were rinsed with PBS, and stained with 10 µM DCFH-DA for 30 min at 37 • C. The cells were washed twice with PBS and incubated with diverse doses of fucoidan for 1 h at 37 • C and 5% CO 2 condition. The cells were rinsed with PBS. The fluorescent DCF intensity was observed through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was performed triplicate.
Intracellular Level of Free Ca 2+
ES-2 and OV-90 cell lines were incubated on 6-well plates for 24 h in no-FBS medium. The cells were incubated with fucoidan (0, 25, 50, 100, 200, and 300 µg/mL) or co-treatment of fucoidan (300 µg/mL) and calcium chelators including 2-aminoethoxydiphenyl borate (2-APB; D9754, Sigma-Aldrich, St. Louis, MO, USA), 1,2-bis(2-aminophenoxy)ethane-N,N,N ,N -tetraacetic acid tetrakis (acetoxymethyl ester; BAPTA/AM; sc-202488, Santa Cruz Biotechnology, Dallas, TX, USA), or ruthenium red for 48 h at 37 • C and 5% CO 2 . The cells were collected through 0.25% trypsin-EDTA and washed through medium before staining with 3 µM Fluo-4 acetoxymethyl (AM) ester (Invitrogen, Carlsbad, CA, USA) at 37 • C and 5% CO 2 for 20 min. Fluorescent intensity was observed through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was repeated three times.
Measurement of Mitochondrial Ca 2+ Concentration
ES-2 and OV-90 cell lines were incubated on 6-well plates 24 h in no-FBS medium. The cells were then incubated with fucoidan (0, 25, 50, 100, 200, and 300 µg/mL) or a combination of fucoidan (300 µg/mL) with 2 µM 2-APB, 16 µM BAPTA/AM or 2 µM ruthenium red for 48 h at 37 • C and 5% CO 2 . The cells were collected through 0.25% trypsin-EDTA and washed through medium before staining with 3 µM Rhod-2 and incubated at 4 • C for 30 min. Fluorescence was observed through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was repeated three times.
Observation of Mitochondrial Membrane Potential
Mitochondrial membrane potential (MMP) were determined through a mitochondria staining kit (Sigma-Aldrich, St. Louis, MO, USA). The ovarian cancer cell lines were incubated with fucoidan (0, 25, 50, 100, 200, and 300 µg/mL) for 48 h at 37 • C and 5% CO 2 . The cells were stained with 200 × JC-1 at 37 • C and 5% CO 2 for 20 min. The cells were rinsed before observation. Fluorescence was observed through Guava easyCyte™ 5 Flow Cytometer (Merck Millipore, Burlington, MA, USA). The experiment was conducted triplicate.
TUNEL Assay
ES-2 and OV-90 cell lines were incubated on confocal dish and then starved for 24 h in no-FBS media. Then fucoidan was treated at 37 • C and 5% CO 2 for 48 h. After treatment, the ovarian cancer cells were fixed with 4% paraformaldehyde-PBS for 1 h. The ovarian cancer cells were washed with PBS and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min 4 • C. TUNEL (terminal deoxynucleotidyl transferase dNTP nick end labeling) In Situ Cell Death Detection kit, TMR red (Roche, Basel, Switzerland) was used for staining for 1 h at 37 • C in the dark. The ovarian cancer cells were rinsed with PBS and double stained with DAPI (Sigma-Aldrich, St. Louis, MO, USA). Fluorescence intensity was detected through a LSM710 (Carl Zeiss, Oberkochen, Germany) confocal microscope.
Western Blot Analysis
The ovarian cancer cell lines were rinsed twice with chilled PBS (Ca 2+ and Ma 2+ ), then scrapped off the ovarian cancer cells with lysis buffer, the lysates were incubated for 30 min on ice. The supernatant was separated by centrifugation at 21,000× g, 4 • C for 15 min. The protein concentrations were measured by a Bradford assay (Bio-Rad, Hercules, CA, USA). Then we quantified the protein 20 µg and made equal volume of loading mixture. Denatured proteins were separated by SDS-PAGE, and transferred to nitrocellulose membranes. Membranes were observed through chemiluminescence detection (SuperSignal West Pico, Pierce, Rockford, IL, USA) and calculated by ChemiDoc EQ system and Quantity One software (Bio-Rad, Hercules, CA, USA). Total proteins and α-tubulin (TUBA) were used to calculate the activation of target signals.
In Vivo Toxicity and Xenograft Analysis
Wild-type Danio rerio were bred according to Korea University guidelines at 28.5 • C with 10 h/14 h dark/light cycles. To evaluate the toxicity of fucoidan, zebrafish embryos were obtained from natural spawning between one male and two female adult fish. The embryos were transferred to 24-well plates (n = 10, per well) under each condition and cultured for 24 h in 0.3% Danieau's buffer (1740 mM NaCl, 21 mM KCl, 12 mM MgSO 4 ·7H 2 O, 18 mM Ca(NO 3 ) 2 , and 150 mM HEPES), and the fucoidan-exposed zebrafish larvae were evaluated for an additional 48 h. Viability, heartbeat, and malformation were evaluated as toxicity indicators. To establish a zebrafish xenograft model, ES-2 and OV-90 cell lines were first incubated with fucoidan for 22 h. Then, the cells were incubated for 2 h with CM-Dil dye (4 µM, Invitrogen, Carlsbad, CA, USA) as a cell tracker. Both cells (1 × 10 2 cells) were injected into the yolk sac of zebrafish anesthetized with 0.02% tricaine (Sigma-Aldrich, St. Louis, MO, USA) 48 h post fertilization through a PV820 microinjector (World Precision Instruments, Sarasota, FL, USA). After the incubation of the zebrafish at 28.5 • C for 72 h in 24-well plates, the fluorescence of the zebrafish was measured using a fluorescence microscope (DM3000, Leica, Wetzlar, Germany). Red fluorescent tumors were estimated through ImageJ software (U.S. National Institute of Health, Bethesda, MD, USA).
In Vivo Apoptosis Analysis
The cell apoptosis in the zebrafish was determined using acridine orange staining. Zebrafish (n = 10) were incubated to each concentration of fucoidan for 48 h and were transferred to 5 µg/mL of Danieau's buffer containing acridine orange followed by incubation in the dark for 1 h. After staining with acridine orange, the zebrafish embryos were rinsed twice with Danieau's buffer and visualized using a fluorescence microscope (DM3000, Leica, Wetzlar, Germany).
Analysis of Angiogenesis in Transgenic Zebrafish
The larvae of the transgenic zebrafish were incubated with the fucoidan for 48 h, and GFP expression patterns of 10 zebrafish larvae per condition were evaluated. Images were observed using a fluorescence microscope (DM3000, Leica, Wetzlar, Germany).
RNA Isolation
Total RNA was extracted through TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was confirmed by agarose gel electrophoresis to identify RNA quality.
Quantitative PCR Analysis
All primers as illustrated in Table 2 were produced by Bioneer (Daejeon, Korea) according to GenBank database using Primer 3 (ver. 4.0.0). Quantitative PCR was conducted using SYBR Green (Sigma-Aldrich, St. Louis, MO, USA) and a StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). Gene expression was estimated by C T value (cycle number). Compared gene expression was calculated by the 2 −∆∆CT method. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene in human and zebrafish was used as the normalization of gene expression.
Significances
Quantitative analysis was identified through (ANOVA). All experiments were performed triplicate. All analysis of significance was identified through the error terms. A p-value ≤ 0.05 indicated statistical significance. Data is expressed as least-square means (LSMs) with standard errors. 
Conclusions
Collectively, we provided the first evidence, to our knowledge, of fucoidan-mediated cell apoptosis in human ovarian cancer cells and in zebrafish models. Fucoidan induced the depolarization of MMP and the production of ROS, leading to the overload of calcium concentration in cytosol and mitochondria in both ES-2 and OV-90 cells. These effects were caused by the decrease in the expression of signaling kinases involved in PI3K/MAPK cascades in ovarian cancer. Additionally, the inhibition of both cascades by inhibitors before fucoidan incubation affected the decrease in the phosphorylation of target signals and a reduction in the cell growth of ES-2 and OV-90 cells. Moreover, fucoidan triggered apoptotic proteins, induced ER stress, and decreased the expression of angiogenesis-related genes in ES-2 and OV-90 cells and exhibited synergistic effects with cisplatin or paclitaxel. Furthermore, fucoidan interrupted tumor and vascular formation in zebrafish xenograft and fli1 Tg model, respectively, whereas it did not exhibit toxicity in normal zebrafish. Thus, fucoidan can be a novel therapeutic agent through its ability to prevent the progression of ovarian cancer. However, this study also raises concerns about the effects of fucoidan in clinical application. Exposure to fucoidan in zebrafish larvae without a tumor slightly reduced larval development. This suggests that fucoidan may cause non-target effects on normal cells, not just cancer cells. Further research will increase the therapeutic efficiency of fucoidan to target specifically to cancer cells if the dose, time, and molecular targets for fucoidan-based therapy.
